10
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Fenfluramhe plasma concentrations after administration of a sustained-release capsule formulation and rapid-release tablets

, , &
Pages 160-168 | Accepted 20 Oct 1978, Published online: 21 Aug 2008

References

  • Armitage P. Chapter 7. Statistical Methodsin Medical Research. Blackwell, Oxford 19711. Armitage P. Chapter 7. Statistical Methodsin Medical Research. Blackwell, Oxford 1971
  • Ayd F. J., Jr. Single daily dose of anti-depressant. J.A.M.A. 1974; 230: 3632. Ayd F. J., Jr. Single daily dose of anti-depressant. J.A.M.A. 1974; 230: 363
  • Campbell D. B. Gas chromatographic measurement of levels of fenfluramine and norfenfluramine in human plasma, red cells and urine following therapeutic doses. J. Chromatogr. 1970; 49: 4423. Campbell D. B. Gas chromatographic measurement of levels of fenfluramine and norfenfluramine in human plasma, red cells and urine following therapeutic doses. J. Chromatogr. 1970; 49: 442
  • Campbell D. B. Plasma concentrations of fenfluramine and its metabolite norfenfluramine following single and repeated oral administration. Br. J. Pharmacol. 1971; 43: 4654. Campbell D. B. Plasma concentrations of fenfluramine and its metabolite norfenfluramine following single and repeated oral administration. Br. J. Pharmacol. 1971; 43: 465
  • Gatley M. S. “To be taken as directed”. J R. Coll. Gen. Practit. 1968; 16: 395. Gatley M. S. “To be taken as directed”. J R. Coll. Gen. Practit. 1968; 16: 39
  • Hooper A. C. A clinical trial of a new fenfluramine preparation (Ponderax PA). Postgrad. Med. J. 1975; 51: 155, Suppl. 16. Hooper A. C. A clinical trial of a new fenfluramine preparation (Ponderax PA). Postgrad. Med. J. 1975; 51: 155, Suppl. 1
  • Maneshka S. Prolonged action fenfluramine capsule versus fenfluramine tablets in general practice. Br. J. Clin. Pract. 1975; 29: 127. Maneshka S. Prolonged action fenfluramine capsule versus fenfluramine tablets in general practice. Br. J. Clin. Pract. 1975; 29: 12
  • Munro J. F. 1978, Personal communication.8. Munro J. F. 1978, Personal communication.
  • Noble R. E. Effect of prolonged-action fenfluramine on weight and blood lipids in obese patients. Curr. Med. Res. Opin. 1979; 6: 169, Suppl. 19. Noble R. E. Effect of prolonged-action fenfluramine on weight and blood lipids in obese patients. Curr. Med. Res. Opin. 1979; 6: 169, Suppl. 1
  • Owen J. H. Prolonged action fenfluramine in general practice. Br. J. Clin. Pract. 1975; 29: 1310. Owen J. H. Prolonged action fenfluramine in general practice. Br. J. Clin. Pract. 1975; 29: 13
  • Pinder R. M., Brogden R. N., Sawyer P. R., Speight T. M., Avery C. S. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 1975; 10: 24111. Pinder R. M., Brogden R. N., Sawyer P. R., Speight T. M., Avery C. S. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 1975; 10: 241
  • Riveline R. Analysis of the metabolic activity of prolonged-acting fenfluramine in clinical practice. Curr. Med. Res. Opin. 1979; 6: 236, Suppl. 112. Riveline R. Analysis of the metabolic activity of prolonged-acting fenfluramine in clinical practice. Curr. Med. Res. Opin. 1979; 6: 236, Suppl. 1
  • Spriet A., Beiler D. Table to facilitate the determination of symmetrical confidence intervals in bioavailability trials with Westlake's method. Eur. J. Drug Metabol. Pharmacol 1978; 2: 12913. Spriet A., Beiler D. Table to facilitate the determination of symmetrical confidence intervals in bioavailability trials with Westlake's method. Eur. J. Drug Metabol. Pharmacol 1978; 2: 129
  • Sproule B. C. Treatment of the grossly obese with a high dose of fenfluramine. S. Afr. Med. J. 1978; 45: 46, Suppl.14. Sproule B. C. Treatment of the grossly obese with a high dose of fenfluramine. S. Afr. Med. J. 1978; 45: 46, Suppl.
  • Westlake W. J. The use of balanced incomplete block designs in comparative bioavailability trials. Biometrics 1974; 30: 31915. Westlake W. J. The use of balanced incomplete block designs in comparative bioavailability trials. Biometrics 1974; 30: 319
  • Wagner J. G. Biopharmaceutics and Relevant Pharmacokinetics. Drug Intelligence Publications Inc., Hamilton 1971; 14016. Wagner J. G. Biopharmaceutics and Relevant Pharmacokinetics. Drug Intelligence Publications Inc., Hamilton 1971; 140
  • Wagner J. G. Chapter 8. The Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications Inc., Hamilton 197517. Wagner J. G. Chapter 8. The Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications Inc., Hamilton 1975
  • Wagner J. G., Nelson D. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J. Pharm. Sci. 1964; 53: 139218. Wagner J. G., Nelson D. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J. Pharm. Sci. 1964; 53: 1392

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.